Abstract 1014TiP
Background
Currently, 70%-80% of liver cancer patients have recurrence within 5 years after radical surgery. Therefore, determining effective treatment methods for liver cancer is still a major issue of global concern. Recombinant human adenovirus type 5 (rAd5, H101) is the world's first approved oncolytic virus product in China, rAd5 and transarterial chemoembolization (TACE) has significant anti-tumor effect in treatment of liver cancer. Compared with TACE, transhepatic arterial embolization (TAE) sequential thermal ablation may significantly improve the overall survival (OS) rate of liver cancer patients. This study aims to explore the efficacy and safety of rAd5 combined with TAE sequential thermal ablation in treatment of liver cancer, and to further explore the local and systemic immunological changes in patients.
Trial design
This is a prospective, open-label, randomized, parallel controlled study, 110 patients with medium- and high-risk recurrent liver cancer are expected to enroll. Key inclusion criteria are: age ≥18 and ≤70; ECOG performance status of 0-1; Child-Pugh score ≤7; and the expected survival time ≥3 months. All participants are randomized 1:1 to receive rAd5 combined with TAE and thermal ablation (experimental group) or TAE and thermal ablation (control group). Before, 10 mg dexamethasone was intravenously administered. rAd5 (H101) will be intratumorally injected into the hepatic segmental artery, the dosage is adjusted according to the maximum diameter of lesions: ≤10 cm, 1.0×1012 vp/day; ≥10 cm, 1.5×1012 vp/ day, 28 days for a cycle (4 cycles totally). 1-3 weeks after rAd5 injection and TAE or TAE, thermal ablation treatment will be performed if patients have residual tumor. Patients will be followed up at 1, 3, 6 and 12 months after treatment. The primary endpoint is objective response rate. Secondary endpoints include progression free survival, disease control rate, one-year OS and quality of life score. Exploratory endpoints are the changes from baseline in CD4+, CD8+, Treg, Th1 and Th2. The adverse events will be monitored.
Clinical trial identification
ChiCTR2300067319 (http://www.chictr.org.cn/); Release date, January 04, 2023.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18